Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Martin Hutchings et al. published in the Journal of Clinical Oncology:
“An unmet need persists for effective therapies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) – especially high-grade B-cell lymphoma (HGBCL) and post–CAR T-cell settings.
Phase Ib/II trial (NCT03533283) evaluated glofitamab plus polatuzumab vedotin (Glofit-Pola) in 129 patients with R/R LBCL (34% HGBCL; 22% prior CAR T).
Key findings:
- Overall response rate: 78%
- Complete response rate: 60%
- Median PFS: 12.3 mo
- Median OS: 33.8 mo
- Most common AE: cytokine release syndrome (43%; mostly grade 1–2)
Takeaway: Glofit-Pola achieved high and durable responses with manageable safety, even in heavily pretreated and post–CAR T patients – highlighting its promise in this difficult-to-treat population.”
Title: Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Authors: Martin Hutchings, Anna Sureda, Francesc Bosch, Thomas Stauffer Larsen, Paolo Corradini, Abraham Avigdor, María José Terol, Antonio Rueda Dominguez, Antonio Pinto, Alan Skarbnik, Raul Cordoba, Judit Meszaros Jørgensen, Pier Luigi Zinzani, Wilfred Leung, Alessia Bottos, Donghang Li, James Relf, Maneesh Tandon, Gila Sellam, Giuseppe Gritti
Read the full article in the Journal of Clinical Oncology.
Read more posts featuring Yan Leyfman on OncoDaily.